September 06, 2026 05:29 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Hindutva influencer Swatantra Bhardwaj detained after viral assault clip; Chirag Paswan’s party files complaint for ‘falsely’ naming him | Bengaluru horror: Woman stripped, assaulted and filmed over unpaid loan interest; 4 arrested | West Bengal CM's big warning: Teacher suspended over tilak row, govt employee punished for PM Modi post | Tragedy on Kerala Highway: 8 Tamil Nadu students killed after car crashes into parked lorry | Influencer Swatantra Bhardwaj, accused of assaulting CJP protester's father, detained in UP | Yasin Malik’s double shock from jail: Announces divorce, refuses to defend himself in Sarla Bhat case | Sonia Gandhi’s memoir finds new publisher as HarperCollins steps in amid Penguin row | 1,000 RSS-backed schools in Bengal? Suvendu Adhikari sets one-year target | PM Modi hails Giorgia Meloni on becoming longest-serving postwar Italian PM | HarperCollins to publish Sonia Gandhi’s memoir amid Penguin row
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.